Gulf International Bank UK Ltd Buys 98 Shares of Illumina, Inc. (NASDAQ:ILMN)

Gulf International Bank UK Ltd grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.7% in the 1st quarter, HoldingsChannel.com reports. The fund owned 13,562 shares of the life sciences company’s stock after acquiring an additional 98 shares during the period. Gulf International Bank UK Ltd’s holdings in Illumina were worth $1,862,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. VisionPoint Advisory Group LLC raised its stake in Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after buying an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new position in Illumina in the fourth quarter worth approximately $37,000. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after buying an additional 132 shares in the last quarter. Gradient Investments LLC raised its stake in Illumina by 375.0% in the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after buying an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. raised its stake in Illumina by 183.0% in the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock worth $42,000 after buying an additional 194 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of ILMN opened at $108.57 on Friday. The firm has a market capitalization of $17.30 billion, a PE ratio of -13.32 and a beta of 1.20. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $202.85. The company’s fifty day moving average price is $112.71 and its 200-day moving average price is $127.62.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the prior year, the company earned $0.08 earnings per share. The firm’s revenue was down 1.0% on a year-over-year basis. On average, equities research analysts predict that Illumina, Inc. will post 1.04 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on ILMN. Evercore ISI reduced their price objective on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research note on Tuesday, June 11th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Barclays lifted their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. Finally, StockNews.com assumed coverage on shares of Illumina in a report on Saturday. They issued a “buy” rating on the stock. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $158.14.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.